{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:52:53Z","timestamp":1649087573718},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00347-016-0389-3","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T09:58:01Z","timestamp":1478253481000},"page":"639-645","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Was bringt die Anti-VEGF-Therapie im Klinikalltag?"],"prefix":"10.1007","volume":"114","author":[{"given":"K.","family":"Wiesinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Reinelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ennemoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Edelmayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Sch\u00f6nherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"issue":"2","key":"389_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archophthalmol.2007.53","volume":"126","author":"SB Bressler","year":"2008","unstructured":"Bressler SB, Mu\u00f1oz B, Solomon SD, West SK, Salisbury Eye Evaluation (SEE) Study Team (2008) Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol 126(2):241\u2013245","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"389_CR2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908","journal-title":"N Engl J Med"},{"issue":"78","key":"389_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","volume":"19","author":"U Chakravarthy","year":"2015","unstructured":"Chakravarthy U et al (2015) A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technol Assess 19(78):1\u2013298","journal-title":"Health Technol Assess"},{"key":"389_CR4","unstructured":"Hackl (2001) Off Label Use. In: Rieger (Hrsg) Lexikon des Arztrechts. (Beitrag 3910, 2)"},{"key":"389_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1792-8","author":"KR Koch","year":"2012","unstructured":"Koch KR, Muether PSH, Hermann MM, Hoerster R, Kirchhof B, Fauser S (2012) Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007\/s00417-011-1792-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"389_CR6","volume-title":"\u00dcber Struktur und Vielfaltim \u00d6ffentlichen Recht","author":"Kopetzki","year":"2008","unstructured":"Kopetzki (2008) \u201eOff-label-use\u201c von Arzneimitteln. In: Enn\u00f6ckl D, Raschauer N, Schulev-Steindl E, Wessely W (Hrsg) \u00dcber Struktur und Vielfaltim \u00d6ffentlichen Recht, Bd. 77. Springer, New York. ISBN: 978-3-211-79379-4"},{"issue":"3","key":"389_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, MANTA Research Group, - (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97(3):266\u2013271","journal-title":"Br J Ophthalmol"},{"key":"389_CR8","volume-title":"Augenheilkunde. Verstehen \u2013 lernen \u2013 anwenden","author":"GK Lang","year":"2008","unstructured":"Lang GK (2008) Augenheilkunde. Verstehen \u2013 lernen \u2013 anwenden Bd. 4. Thieme Verlagsgruppe, Stuttgart"},{"issue":"6","key":"389_CR9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve- week results of an uncontrolled open-label clinical study. Ophthalmology 112(6):1035\u20131047","journal-title":"Ophthalmology"},{"issue":"11","key":"389_CR10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"AA Moshfeghi","year":"2006","unstructured":"Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113(11):e1\u2013e12","journal-title":"Ophthalmology"},{"issue":"4","key":"389_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36(4):331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"1","key":"389_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-008-0952-y","volume":"247","author":"JS Schouten","year":"2009","unstructured":"Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247(1):1\u201311","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"389_CR13","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","volume":"340","author":"A Tufail","year":"2010","unstructured":"Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W, ABC Trial Investigators (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double Masked study. BMJ 340:c2459","journal-title":"BMJ"},{"key":"389_CR14","volume-title":"Wei\u00dfbuch zur Situation der ophthalmologischen Versorgung in Deutschland","author":"W Pfeiffer","year":"2012","unstructured":"Pfeiffer W, Deutsche Ophthalmologische Gesellschaft (2012) Wei\u00dfbuch zur Situation der ophthalmologischen Versorgung in Deutschland Bd. 7. Deutsche Ophthalmologische Gesellschaft, M\u00fcnchen"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-016-0389-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0389-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0389-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T08:17:12Z","timestamp":1568535432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-016-0389-3"}},"subtitle":["Wirksamkeit von Anti-VEGF-Therapie bei Patienten mit Makulaerkrankungen in der Klinikroutine an 1492 Augen in \u00d6sterreich"],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s00347-016-0389-3","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}